BioMarin Drops Lower Dose of its Hemophilia Gene Therapy as it Eyes Submissions by Year-End

BioMarin are dropping the 4e13 dose for thier Hemophilia A gene therapy and are going for 6e13 for all. They are trying to aim for a 1 year data on 130 patients by early 2021.


Click Here to read the full article



Subscribe and Get Breaking News Sent to Your Inbox!

  • White Instagram Icon
  • White Facebook Icon

© 2019- 2020 HEMO TIMES IS A SUBSIDIARY OF RARE HEALTH NETWORK, LLC